Carna Biosciences
OverviewSuggest Edit
Carna Biosciences is a company engaged in drug discovery support as well as drug discovery and development. It provides drug discovery supporting products and services including kinase protein, profiling services, assay development, crystallography, cell-based assay services, etc. The company also identifies and develops medicines for the treatment of cancer and inflammatory diseases using its kinase drug discovery platform, QuickScout.
| Type | Public | |
| Founded | 2003 | |
| HQ | Kobe, JP | Map |
| Website | carnabio.com |
Key People/Management at Carna Biosciences
Kohichiro Yoshino
President and Chief Executive Officer Representative Director
Norio Aikawa
Head of Drug Discovery and Support Business Head of IP and Legal Department Director
Masaaki Sawa
Chief Scientific Officer, Director
Emi Yamamoto
Chief Financial Officer, Director President of CarnaBio USA, Inc.
Atsuo Arita
Outside Director
Tsuguo Ogasawara
Outside Director
Carna Biosciences Office Locations
Carna Biosciences has offices in Kobe and Natick
Kobe, JP (HQ)
1-chōme-5-5 Minatojima Minamimachi, Chūō-ku
Natick, MA, US
209 W Central St #307
Carna Biosciences Financials and Metrics
Carna Biosciences Revenue
| USD | |
|---|---|
Market capitalization (12-May-2022) | 142.6m |
Closing stock price (12-May-2022) | 10.8 |
Cash (31-Dec-2021) | 3.8b |
EV | (3.1b) |
Carna Biosciences's current market capitalization is $142.6 m.
Annual
| JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 1.4b | 4.9b | 4.3b | 3.8b |
Accounts Receivable | 87.9m | 117.5m | 129.2m | 1.2b |
Inventories | 110.8m | 99.4m | 104.5m | 110.5m |
Quarterly
| JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 1.2b | 1.3b | 4.6b | 5.2b | 4.9b | 4.7b | 3.7b | 3.2b | 3.8b |
Accounts Receivable | 101.0m | 2.2b | 185.9m | 108.2m | 91.0m | 91.2m | 98.1m | 73.9m | 64.9m |
Inventories | 105.5m | 103.7m | 104.5m | 89.2m | 91.8m | 99.0m | 112.2m | 110.6m | 109.8m |
Annual
| JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | (1.2b) | 913.1m | (1.1b) | (532.5m) |
Depreciation and Amortization | 12.7m | 9.4m | 12.4m | 19.2m |
Inventories | 7.2m | 11.4m | (5.1m) | (6.0m) |
Accounts Payable | (2.5m) | 2.7m | (1.7m) | 776.0k |
Quarterly
| JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.4b | (396.3m) | (780.8m) | ||||||
Depreciation and Amortization | 3.7m | 5.7m | 9.1m | ||||||
Inventories | 7.1m | 7.6m | (6.1m) | ||||||
Accounts Payable | 3.0m | (3.2m) | (1.4m) |
Carna Biosciences Revenue Breakdown
Carna Biosciences revenue breakdown by business segment: 44.1% from THE DRUG DISCOVERY SUPPORT and 55.9% from THE DRUG DISCOVERY
Carna Biosciences Cybersecurity Score
Carna Biosciences Environment, Social & Governance (ESG) Ratings
Carna Biosciences Online and Social Media Presence
Carna Biosciences's Trends
Carna Biosciences News and Updates
February 02, 2022
Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences
Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism
Carna Biosciences Blogs
April 19, 2022
Two RET mutant kinases have been newly added to our lineup!
Two(2) RET mutant kinase products have been newly added to our lineup! Cat# 08-572 RET(G810C) Cat# 08-573 RET(G810R) Carna's Kinase Proteins are all produced 100% in-house and will assist your kinase drug discovery with its proven quali…
April 14, 2022
Chinese Website Released！ 中文网站发布!
Carna's Services ＆Products website in Chinese has been released. Check it out from here! Carna的中文服务和产品网站已经发布。 从这里查看!
April 11, 2022
Carna Presented AS-1763 Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
On April 11, 2022, Carna presented two posters highlighting the drug discovery and the result of the SAD part of Phase 1 study for BTK inhibitor AS-1763 at the American Association for Cancer Research (AACR) 2022 Annual Meeting in New Orleans, Louisiana.
Carna Biosciences Frequently Asked Questions
When was Carna Biosciences founded?
Carna Biosciences was founded in 2003.
Who are Carna Biosciences key executives?
Carna Biosciences's key executives are Kohichiro Yoshino, Norio Aikawa and Masaaki Sawa.
How many employees does Carna Biosciences have?
Carna Biosciences has 64 employees.
Who are Carna Biosciences competitors?
Competitors of Carna Biosciences include Jiangsu Hansoh Pharmaceutical Group, SK Biopharmaceuticals and Gracell.
Where is Carna Biosciences headquarters?
Carna Biosciences headquarters is located at 1-chōme-5-5 Minatojima Minamimachi, Chūō-ku, Kobe.
Where are Carna Biosciences offices?
Carna Biosciences has offices in Kobe and Natick.
How many offices does Carna Biosciences have?
Carna Biosciences has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies